A Pre-Clinical Safety Evaluation of SBP (HBsAg-Binding Protein) Adjuvant for Hepatitis B Vaccine.
Although adjuvants are a common component of many vaccines, there are few adjuvants licensed for use in humans due to concerns about their toxic effects. There is a need to develop new and safe adjuvants, because some existing vaccines have low immunogenicity among certain patient groups. In this st...
Main Authors: | Jingbo Wang, Caixia Su, Rui Liu, Baoxiu Liu, Inam Ullah Khan, Jun Xie, Naishuo Zhu |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5245819?pdf=render |
Similar Items
-
Performance Evaluation of an Improved HBsAg Assay (HBsAg NEXT) for the Detection of HBsAg Levels
by: Ekta Gupta, et al.
Published: (2023-12-01) -
HBsAg in Cord Blood Qf Newborns of HBsAg-Positive Mothers
by: Adnan S. Wiharta, et al.
Published: (2018-11-01) -
Circulating immune complexes and mutations of HBsAg are associated with the undetectable HBsAg in anti-HBs and HBeAg positive occult hepatitis B virus infection
by: Ying Yan, et al.
Published: (2022-11-01) -
Role of HBsAg Neutralisation Test in Low Positive and Indeterminate HBsAg Results by Electrochemiluminescence
by: Mridula Madiyal, et al.
Published: (2024-03-01) -
Characteristics and clinical treatment outcomes of chronic hepatitis B children with coexistence of hepatitis B surface antigen (HBsAg) and antibodies to HBsAg
by: Yingping Gu, et al.
Published: (2024-02-01)